Combination Chemistry: Structure–Activity Relationships of Novel Psychoactive Cannabinoids
Originally developed as research tools for use in structure–activity relationship studies, synthetic cannabinoids contributed to significant scientific advances in the cannabinoid field. Unfortunately, a subset of these compounds was diverted for recreational use beginning in the early 2000s. As these compounds were banned, they were replaced with additional synthetic cannabinoids with increasingly diverse chemical structures. This chapter focuses on integration of recent results with those covered in previous reviews. Whereas most of the early compounds were derived from the prototypic naphthoylindole JWH-018, currently popular synthetic cannabinoids include tetramethylcyclopropyl ketones and indazole-derived cannabinoids (e.g., AB-PINACA, AB-CHMINACA). Despite their structural differences, psychoactive synthetic cannabinoids bind with high affinity to CB1 receptors in the brain and, when tested, have been shown to activate these receptors and to produce a characteristic profile of effects, including suppression of locomotor activity, antinociception, hypothermia, and catalepsy, as well as Δ9-tetrahydrocannabinol (THC)-like discriminative stimulus effects in mice. When they have been tested, synthetic cannabinoids are often found to be more efficacious at activation of the CB1 receptor and more potent in vivo. Further, their chemical alteration by thermolysis during use and their uncertain stability and purity may result in exposure to degradants that differ from the parent compound contained in the original product. Consequently, while their intoxicant effects may be similar to those of THC, use of synthetic cannabinoids may be accompanied by unpredicted, and sometimes harmful, effects.
KeywordsCannabinoids Indoles JWH-018 Receptor binding Synthetic cannabinoids THC
Preparation of this review was supported in part by National Institute on Drug Abuse grant DA-003672; NIDA had no further role in the writing of the review or in the decision to submit the paper for publication.
- 24.Holley P, Wan W (2015) Deadly Chinese drugs are flooding the U.S., and police can’t stop them. Washington Post: Washington, DCGoogle Scholar
- 27.Brents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE et al (2012) Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol 83:952–961CrossRefGoogle Scholar
- 48.Thomas BF, Endres GW, Wiley JL, Pollard GT, Decker AM, Gay EA, Patel PR, Kovach AL, Grabenauer M. (2015). Chemical exposures and risks associated with vaporization and inhalation of synthetic cannabinoids. Paper presented at the annual meeting of the International Cannabinoid Research Society, Wolfville, Nova Scotia, CanadaGoogle Scholar
- 52.Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M et al (2015) Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chem Neurosci 6:1546–1559CrossRefGoogle Scholar
- 56.Uchiyama N, Shimokawa Y, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (2014) Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 3,4,5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-N-NBOMe, identified in illegal products. Forensic Toxicol 32:105–115CrossRefGoogle Scholar
- 57.Drug Enforcement Agency (2015) Schedules of controlled substances: temporary placement of three synthetic cannabinoids into schedule I. Final order. Fed Regist 80:5042–5047Google Scholar
- 63.Yao BB, Hsieh G, Daza AV, Fan Y, Grayson GK, Garrison TR et al (2009) Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging. J Pharmacol Exp Ther 328:141–151CrossRefGoogle Scholar
- 65.Huffman JW, Zengin G, Wu MJ, Lu J, Hynd G, Bushell K et al (2005) Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. Bioorg Med Chem 13:89–112CrossRefGoogle Scholar
- 88.Center for Disease Control and Prevention (2013) Acute kidney injury associated with synthetic cannabinoid use - multiple States, 2012. MMWR Morb Mortal Wkly Rep 62:93–98Google Scholar
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 2.5 International License (http://creativecommons.org/licenses/by-nc/2.5/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.